anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stabilized TCR constructs comprising a TCR alpha chain polypeptide having a variable alpha (V?) domain and a constant alpha (C?) domain and a TCR beta chain polypeptide having a variable beta (V?) domain and a constant beta (C?) domain. The TCR constructs are stabilized by the introduction into the C? domain and/or the C? domain of stabilizing mutations such as non-naturally occurring disulfide bonds between the C? domain and the C? domain (an interchain disulfide bond), non-naturally occurring intrachain disulfide bonds, point mutations, loop truncation mutations, and combinations thereof. TCR fusion proteins comprising one or more of the TCR constructs and a scaffold and/or other biologically active moiety are also described.
The study consisted of a 2-week screening period (visit 1), a 20-week treatment period beginning with a baseline visit in which randomization was completed and study drug treatment began (visits 2 through 7), and a final assessment was performed 4 weeks after the last dose of study drug (visit 8 \[week 24 or early termination\]). Participants were randomized to receive either CEP-33457 or placebo subcutaneously (SC) every 4 weeks. Plasma samples for measurement of study drug concentration were collected in a subset of participants and study drug was administered at each study visit until the final visit. The dose of background steroid medication may have been increased, if needed, to treat the participant for minor fluctuations in lupus disease activity. One interim analysis was conducted when at least 80 participants completed Week 12 or had been withdrawn from the study. Participants who completed the treatment period returned to the study center 4 weeks after the last dose had been administered for final procedures and assessments. Final procedures and assessments for participants who withdrew from the study before 20 weeks of treatment were performed at the last visit. Final procedures and assessments for participants who participated in the study beyond week 24 were to be performed at the next regularly scheduled visit. Participants who complete the study will be eligible for participation in the 12-month open-label study (study C33457/3075; herein referred to as study 3075) to assess continued effectiveness and safety of the CEP-33457 treatment.
Patients receive recombinant Flt3 ligand IT on days 1-5 and undergo radiation therapy on day 8 or 9. Patients also receive agonistic anti-CD40 monoclonal antibody CDX-1140 IT and Poly-ICLC IT on day 9 or 10. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
NEW MATERIAL:An anticoagulation substance originated from human placenta and having the following characteristics. Molecular weight (measured in reduced state and nonreduced state using SDS-polyacrylamide gel electrophoresis), 73,000+ or -2,000; isoelectric point (measured by isoelectric column electrophoresis using ampholite), 6.2-6.6; stability, (i) inactivated by heating at 50 deg.C for 30min, (ii) stable at 5.5-8.5 pH (37 deg.C) and (iii) stable at 37 deg.C for 15min in plasma; action, (i) prolongs the coagulation time by the readdition of calcium, (ii) prolongs prothrombin time and (iii) prolongs activated part thromboplastin time. USE:Anticoagulant having low side effect and high safety. PREPARATION:Human placenta is homogenized and the homogenate is centrifuged. The obtained precipitate is extracted with a chelating agent and the resultant extract is subjected to ammonium sulfate fractionation. The obtained fraction is subjected to conventional separation and purification operations to obtain the objective anticoagulant.
The growing impact of obesity worldwide has consequences on patients' quality of life, numerous weight-related comorbidities, and global economic costs. Numerous therapies for obesity treatment involve lifestyle modifications, pharmacotherapy, and procedural intervention, though many limitations exist. Bariatric surgery has been shown to be the most durable and effective; however, the invasive nature and complications, such as micronutrient deficiencies, often damper enthusiasm for these procedures. Furthermore, it is often unavailable to those with class I or II obesity. Two emerging modalities have shown promising results for sustained weight loss: minimally invasive endoscopic bariatric therapies such as the POSE2.0 procedure and GLP-1 agonists, including Liraglutide. Recent data examining these methods individually have demonstrated weight loss of 5-10% percent total body weight for Liraglutide vs. 15-20% for POSE2.0. No studies have evaluated these therapies head-to-head and in combination. This pilot randomized crossover trial aims to investigate the weight loss outcomes between Liraglutide and POSE2.0 procedure. The investigators will recruit 25 subjects in each of the two intervention groups for a 6-month treatment period with each therapy. At 6 months, if the subject has not attained a BMI less than or equal to 30 kg/m2 in the Liraglutide arm or 28 kg/m2 in the POSE2.0 arm, they will cross over to the other intervention to utilize the combination of POSE2.0 and Liraglutide for additional 6 months. As per clinical guidelines, The cross-over criteria are congruent with accepted clinical guidelines for the use of these interventions. If the patient does not achieve greater than 5% total body weight loss on Lirglutide alone by 3 months as per accepted clinical criteria, the Liraglutide will not be continued as per clinical recommendation and the subject will cross over to the POSE2.0 procedure at 6 months.
The proton therapy or yttrium 90 as a more aggressive down-staging therapy may contribute to change tumor behavior. Lenvatinib is applied to adjuvant therapy after LDLT.
Bedaquiline is a cationic, amphiphilic drug that induced phospholipidosis (at almost all doses, even after very short exposures) in drug-treated animals, mainly in cells of the monocytic phagocytic system (MPS). All species tested showed drug-related increases in pigment-laden and/or foamy macrophages, mostly in the lymph nodes, spleen, lungs, liver, stomach, skeletal muscle, pancreas and/or uterus. After treatment ended, these findings were slowly reversible. Muscle degeneration was observed in several species at the highest doses tested. For example, the diaphragm, esophagus, quadriceps and tongue of rats were affected after 26 weeks of treatment at doses similar to clinical exposures based on AUC comparisons. These findings were not seen after a 12-week, treatment-free, recovery period and were not present in rats given the same dose biweekly. Degeneration of the fundic mucosa of the stomach, hepatocellular hypertrophy and pancreatitis were also seen.
Control group underwent an exercise program planned as 6 sessions. A one-day gap separated each session, and the entire program spanned 11 days. Both groups participated in supervised stretching and strengthening exercises.
PROCEDURE FOR ISOLATING AND PURIFYING RADIOACTIVE LIGATED RHENIUM PHARMACEUTICALS AND USE THEREOF AND KIT            ABSTRACT         A sterile pyrogen free Re186 or Re188 radiopharmaceutical is prepared by reducing radio-active perrhenate in the presence of a bone seeking ligand to form a solution including complexed Re-ligand compound together with impurities such as uncomplexed perrhenate, ReO2 and free ligand.  The radiopharmaceutical is obtained by a low pressure purification method.  The solution is added to a separation column, preferably an ion exchange column, and a first portion is eluted and discarded.  The radiopharmaceutical is collected in a second eluted portion defined as having 25-85% of the activity of the Re on the column, less than 10% unligated perrhenate and less than 1% ReO2.  This can be used as is to image and treat metastatic bone lesions.  A simple kit is also disclosed.
PROBLEM TO BE SOLVED: To provide a curable compsn. for medical treatment useful for clinical application which has excellent biocompatibility, has a form imparting property, does not collapse in spite of contact with the ground material right after grinding with moisture, such as blood, and exhibits excellent characteristics, such as tacky adhesiveness to the bone. SOLUTION: Either of collagen or collagen deriv. or both thereof are incorporated into either or both of the powder part and grinding liquid of the curable compsn. contg. a phosphoric acid component and calcium component in either or both of the powder part and grinding liquid and water-soluble phosphate is incorporated into either or both of the powder part and grinding liquid. The concn. of the phosphoric acid ions of the grinding liquid when the total amt. thereof is dissolved in the grinding liquid is required to be above the concn. of 50 millimol.
Participants will receive the study drugs on Days 1 and 15 of each study cycle,Cycle 1, Participants will receive the drugs on separate days (etigilimab on Day 1 and nivolumab on Day 2). Starting with Cycle 2, you will receive both drugs on Day 1 (separated by 2 hours).
A delivery system of coated and uncoated nanoparticles (NP) for delivery of methylene blue (MB). The delivery system was developed using PLGA-based polymer that was repeatedly shown to be biocompatible and biodegradable. The parameters of synthesized NPs were within the suitable range for BBB permeation—specifically, the NPs were monodispersed, with slight negative charge, and with the size within 100-150 nm range suitable for intravenous delivery and delivery to the brain. The coating on the nanoparticle did not have a significant impact on the nanoparticle size and zeta potential. Based on the immunoblotting experiments using AD cellular model, the GSH coated NPs were better in reducing tau levels compared to MB solution. In vitro BBB Transwell permeation study showed eight fold higher MB-NP permeation compared to the MB solution over 24 hours.
OBJECTIVE: Poor sleep quality is common in patients with schizophrenia but estimated prevalence rates in this population have been mixed. This systematic review and meta-analysis examined the prevalence of poor sleep quality in schizophrenia samples and moderators of prevalence from epidemiological studies as well as the risk of poor sleep quality in schizophrenia patients based on case-control studies.
METHODS: Both international (PubMed, Web of Science, PsycINFO, EMBASE) and Chinese databases [Chinese Nation knowledge Infrastructure (CNKI) and WANFANG] were systematically searched. Studies that estimated the prevalence of poor sleep quality in schizophrenia were analyzed using a random effects model. Funnel plots and Egger's tests were used to assess publication bias. Statistical analyses were performed using R software.
RESULTS: In total, 23 epidemiological studies and nine case-control studies were included. Based on the epidemiological studies, the pooled overall prevalence of poor sleep quality was 63.4 % [95 % confidence interval (CI): 57.0 %-69.9 %]. Additionally, based on the nine case-control studies, schizophrenia patients had a significantly higher risk for poor sleep quality compared to healthy controls [odd ratio (OR) = 4.5; 95%CI: 2.4-8.3; P < 0.0001].
CONCLUSION: Poor sleep quality is common among schizophrenia patients. Considering negative outcomes caused by poor sleep quality, regular screening on poor sleep quality should be conducted and effective interventions should be provided to those in need.
The ATWA LSE program will be implemented following a joint curricula development process with approval from the government in each of the three countries. The 'dose' of the intervention are once-weekly hour-long sessions for both in-school adolescents (session facilitated by teachers) and out-of-school adolescents (sessions facilitated by community leaders) over the course of the academic year (roughly 9 months), or roughly 30 sessions of exposure to the in-depth LSE curriculum.
Stockholm syndrome (SS) is relatively rare, but during the 'Iron Swords' war, several cases were described in which some of the hostages showed identification and empathy with their captors, which presented their families and their caregivers with diagnostic and therapeutic questions. The term SS was coined following a robbery in Stockholm in 1973, after which one of the hostages developed a relationship with the captors. From this and other cases, SS has become a cornerstone in understanding the dynamics of extreme emotional fabric: trauma woven into the survival instinct. Risk factors for SS are described: being in absolute isolation from anyone other than the captor, inability to escape/avoid the situation, receiving gestures of kindness from the captor, all while the victims are under real threat to their physical and emotional integrity. Several theories for the development of SS exist: psychoanalytic theories rely on Ferenczi's concept of "identification with the aggressor," another theory speaks of 'cognitive dissonance' describing the discomfort arising from holding contradictory beliefs and attitudes. A third theory talks about a daily situation where the victims undergo "brainwashing". The fourth theory relies on an evolutionary perspective and speaks of a survival mechanism called conciliation/surrender. This theory emphasizes the survival goal of adapting to life-threatening situations through calming the aggressor and identifying with them. We found this explanation practical and most helpful for those suffering from this syndrome and their relatives. From understanding SS as a survival behavior, the therapeutic principle also arises. The important message in meeting with the returnees is to accept their emotional stance without judgment or anger and to normalize their behavior as a known and understood phenomenon. It is important to convey and mediate to the returnees and their families that this is a survival mechanism that indicates strength and resourcefulness.
PURPOSE:To provide a carcinostatic agent having suppressing effect to various tumors, by extracting Malabar-Kino with water or an organic solvent miscible freely with water, and using the extract as an active component. CONSTITUTION:Malabar-Kino (dried sap of pterocarpus) is extracted with water and/or an organic solvent miscible freely with water (e.g. methanol), and the extract is used as an active component of a carcinostatic agent. Malabar-Kino contains tannins as 70-80% of the component, and was used as a stegnotic in place of gambir in ancient times, and it has been newly found that the substance exhibits excellent suppressing effect to various tumors, e.g. Lewis lung carcinoma, ascites Yoshida sarcoma, etc., and specific inhibiting action to thymine kinase. It can be administered orally or parenterally. Dose: 5-150mg/day for oral administration and 0.1-30mg/day for parenteral administration.
All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
These participants received oral 500 mg Quevir® (Quercetin Phytosome®) tablet, twice a day for 90 days. Each Quevir® tablet contains 200 mg pure Quercetin.
Hepatitis C virus (HCV) infection is a major health problem worldwide. It can cause liver cirrhosis and hepatocellular carcinoma (HCC), making it a cause of morbidity from liver disease. Thus, there is an urgent need for a prophylactic HCV vaccine. Fortunately, modern medicine has transformed the therapy for HCV infection through development of direct-acting antiviral agents (DAAs), achieving high rates of sustained virologic response and giving significant relief from HCC and associated mortality, but unfortunately it fails to eradicate the risk of HCC, especially in HCV-cleared patients with already advanced liver disease. Additionally, DAA-cured patients do not develop sufficient antiviral immunity and are susceptible to reinfection. A comprehensive strategy to control HCV infection must include a vaccine development approach in which the host can develop humoral and cellular immunity to eradicate HCV successfully; however, this remains a challenge as HCV has developed systems to evade immune attacks from its host. This review highlights the current understanding of HCV's effect on liver disease and cancer progression, the nature of immune responses from cell populations interacting with HCV, and the current strategies for vaccine development. The information in this review will advance prophylactic intervention strategies for HCV infection, with the end goal being to prevent chronicity and subsequent liver disease leading to HCC.
Keloids, characterized by excessive scar formation following dermal inflammation, pose a therapeutic challenge due to high recurrence rates. Radiation therapy, contraindicated in children, can minimize recurrence post-surgical removal. Dupilumab, which inhibits the pro-fibrotic interleukin-4/interleukin-13 axis, may effectively manage keloids when intralesional corticosteroid injections are unsuccessful. It may also prevent recurrence post-surgery in pediatric patients. This systematic review assesses the efficacy and safety of dupilumab for the treatment of keloids. Through a systematic search adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we identified and analyzed outcomes from three case reports and three case series studies, totaling 15 patients. Results indicate variable responses to treatment, including significant improvements, no clinical change, and worsening of keloid symptoms. Additional research is needed to recommend using dupilumab to treat keloids (Grade D). Treatment response variability may be linked to differences in interleukin-4/interleukin-13 activity between active and inactive keloids. Additionally, the unintended promotion of T helper 17 cell differentiation by dupilumab may worsen keloids.
A composition is disclosed comprising a carbohydrate-based material a dispersed in carbon dioxide. A general method for synthesizing inexpensive, renewable, non-toxic, non-fluorous, carbohydrate based CO2-philes is disclosed. These CO2-philes are soluble in carbon dioxide. Methods of making the composition are also disclosed. The methods and composition are useful in a variety of applications and can utilize gaseous, liquid and supercritical carbon dioxide. The methods and compositions are useful in the synthesis of surfactants and metal chelates for CO2, as a sizing substrate, in CO2-based coating processes, for impregnation and plasticizing cellulosic and non-cellulosic materials, in pharmaceutical applications, such as crystallization, dispersion and encapsulation of bioactive molecules in solid systems, in the densification of CO2, in the synthesis of biodegradable polymers in CO2, and for carbon dioxide removal, to name just a few.
This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
Infertility occurs in about 15% of all couples. One of the common methods for evaluation of mechanical infertility is hysterosalpingography (HSG). Several reports have shown that this common procedure is associated with moderate pain, i.e. around 5 on a visual analog scale (VAS)of 1-10. It is therefore important to find modes for pain reduction for HSG. According to a report on sonohydrosonograpy, a similar technique using sonography, insertion of media warmed to body temperature into the uterus significantly reduced the pain during the procedure compared with media at room-temprature. The use of room-temperature media is the routine in our institution, as well as in many others. A comparison between the media at different temperatures has not been reported so far.

We plan to perform a prospective trial in which patients referred for HSG will be randomized to the procedure using either warmed or room-temperature media. we will asses pain levels using VAS during the procedure.
Dietary administration of cilostazol to male and female rats and mice for up to 104 weeks, at doses up to 500 mg/kg/day in rats and 1000 mg/kg/day in mice, revealed no evidence of carcinogenic potential. The maximum doses administered in both rat and mouse studies were, on a systemic exposure basis, less than the human exposure at the MRHD of the drug. Cilostazol tested negative in bacterial gene mutation, bacterial DNA repair, mammalian cell gene mutation, and mouse in vivo bone marrow chromosomal aberration assays. It was, however, associated with a significant increase in chromosomal aberrations in the in vitro Chinese Hamster Ovary Cell assay.

In female mice, cilostazol caused a reversible contraceptive effect at a dose (300 mg/kg) that was approximately 7.4-fold greater than the Maximum Recommended Human Dose (MRHD) on a body surface area basis. These findings have not been demonstrated in other animal species.

Cilostazol did not affect fertility or mating performance of male and female rats at doses as high as 1000 mg/kg/day. At this dose, systemic exposures (AUCs) to unbound cilostazol were less than 1.5 times in males, and about 5 times in females, the exposure in humans at the MRHD.
Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.) The treatment will continue for 4 weeks and 3 sessions/ week i.e. thrice a week. The session will be of approximately 20 minutes.
The invention relates to a lotus leaf dripping pill for thirst quenching and body fluid production promoting. The dripping pill is prepared through reasonable compatibility of carefully chosen Chinese herbal medicines. In the past 30 years, the incidence of diabetes in China has a significant increase trend. The typical symptoms of diabetes are 'the three manys and one insufficiency' symptoms, that is, polyuria, polydipsia, polyphagia and emaciation. Some patients with early stage diabetes or in the pre-outbreak stage of the diabetes may have hypoglycemia before lunch or dinner. Diabetic patients also have anorexia, nausea, vomiting, abdominal pain, aggravating diuresis, dizziness, sleepiness, blurred vision, difficult breathing, coma and other symptoms, so the patient's quality of life is seriously influenced. The lotus leaf dripping pill for thirst quenching and body fluid production promoting has the efficacies of third quenching, body fluid production promoting, yin nourishing, dryness moisturizing, heart fire clearing and vexation eliminating, and is especially suitable for preventing diabetes, lobar pneumonia, epidemic encephalitis B, epidemic hemorrhagic fever, gingivitis, infantile summer fever, rheumatoid arthritis etc, and other yin and body fluid deficiency diseases.